Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 66.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,827 shares of the company’s stock after acquiring an additional 1,127 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Crispr Therapeutics were worth $166,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of CRSP. Versant Venture Management LLC acquired a new stake in Crispr Therapeutics in the 1st quarter valued at approximately $210,551,000. Wells Fargo & Company MN grew its holdings in Crispr Therapeutics by 2,044.2% in the 1st quarter. Wells Fargo & Company MN now owns 461,377 shares of the company’s stock valued at $21,089,000 after buying an additional 439,860 shares during the last quarter. NEA Management Company LLC grew its holdings in Crispr Therapeutics by 8.2% in the 1st quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock valued at $159,275,000 after buying an additional 263,736 shares during the last quarter. First Trust Advisors LP acquired a new stake in Crispr Therapeutics in the 2nd quarter valued at approximately $4,998,000. Finally, First Allied Advisory Services Inc. acquired a new stake in Crispr Therapeutics in the 1st quarter valued at approximately $2,695,000. 38.78% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 5,816 shares of the company’s stock, valued at approximately $360,592. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 5,816 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $62.00, for a total value of $360,592.00. Following the sale, the director now directly owns 5,816 shares in the company, valued at approximately $360,592. The disclosure for this sale can be found here. Insiders have sold a total of 29,236 shares of company stock worth $1,877,501 in the last three months. 37.70% of the stock is owned by insiders.

A number of analysts have issued reports on the company. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 13th. ValuEngine raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 10th. Citigroup lowered their target price on Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating on the stock in a report on Friday, August 24th. Finally, Chardan Capital raised their target price on Crispr Therapeutics from $25.00 to $72.50 and gave the company a “buy” rating in a report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.78.

Shares of NASDAQ:CRSP opened at $51.15 on Wednesday. Crispr Therapeutics AG has a 1-year low of $16.16 and a 1-year high of $73.90. The company has a market cap of $2.30 billion, a PE ratio of -29.91 and a beta of 3.29.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative return on equity of 39.58% and a negative net margin of 245.57%. The firm had revenue of $1.09 million for the quarter, compared to analyst estimates of $1.47 million. research analysts expect that Crispr Therapeutics AG will post -2.89 earnings per share for the current fiscal year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Story: Are analyst ratings accurate?

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.